Alpha Tau Medical (DRTS) Free Cash Flow (2021 - 2022)

Alpha Tau Medical (DRTS) posted quarterly Free Cash Flow of -$8.4 million for Q2 2022, down 33.07% on a QoQ basis from -$6.3 million in Q1 2022.

Alpha Tau Medical (DRTS) Free Cash Flow (2021 - 2022) Analysis & Trends

Alpha Tau Medical (DRTS) has reported Free Cash Flow for 2 consecutive years, with -$8.4 million the latest figure, recorded in Q2 2022.

Quarterly Free Cash Flow changed N/A year-over-year to -$8.4 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was -$8.4 million (down 33.07% YoY) and the FY2025 annual result came in at -$32.8 million, down 48.75% from the prior year.
Free Cash Flow slipped to -$8.4 million in Q2 2022 per DRTS's latest filing, from -$6.3 million in the prior quarter.
Over the last five years, Free Cash Flow for DRTS reached as high as -$2.5 million in Q1 2021 and fell as low as -$8.4 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Free Cash Flow (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-19.58 Mn
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	158.09 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-1.53 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	1.29 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	848.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-354.95 Mn
10	Alpha Tau Medical	1.19 Bn	1.11 Bn	-	-

Download Data